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Summary In the year 2000, the ongoing meta-analysis of the Early Breast Cancer Trialists' Collaborative Group will be updated to include
additional data from over 4000 patients treated with luteinizing hormone-releasing hormone analogues, principally goserelin. Four major
international trials are currently in progress to evaluate the safety and efficacy of goserelin in comparison with the current standard treatments
in early breast cancer, which are chemotherapy or tamoxifen. This paper provides an outline of the protocols and main objectives of the
Zoladex Early Breast Cancer Research Association (ZEBRA) trial (goserelin versus cyclophosphamide-methotrexate-5-fluorouracil [CMF]),
the Cancer Research Campaign (CRC) trial (goserelin versus tamoxifen versus the combination of goserelin and tamoxifen versus no further
treatment), the International Breast Cancer Study Group (IBCSG) Vil trial (goserelin versus CMF versus CMF followed by goserelin) and the
Eastern Cooperative Oncology Group (ECOG)/South Western Oncology Group (SWOG) trial (cyclophosphamide-doxorubicin-5-fluorouracil
[CAF] versus CAF followed by goserelin versus CAF followed by goserelin plus tamoxifen). Preliminary results are expected from the CRC
trial in 1998 and from the ZEBRA and ECOG/SWOG trials in 1999. Results from the wide range of comparator regimens, treatment durations
and patient subgroups investigated in these trials will greatly increase the clinical database and should help to define the optimum role for
goserelin in the treatment of early breast cancer in premenopausal women.
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The value of adjuvant ovarian ablation (by irradiation or surgery)
in prolonging long-term survival in premenopausal women with
early breast cancer has been clearly established. The Early Breast
Cancer Trialists' Collaborative Group (EBCTCG) overview of
1996 reported that of2102 patients under 50 years ofage (most of
whom would have been premenopausal at diagnosis), those who
underwent irreversible ovarian ablation showed a highly signifi-
cant improvement in both overall and disease-free survival rates
compared with controls and that this benefit extended to patients
with both node-negative and node-positive disease (Early Breast
Cancer Trialists' Collaborative Group, 1996). This ongoing meta-
analysis will be updated in the year 2000 to include additional
information from the current trials of ovarian suppression with
luteinizing hormone-releasing hormone (LHRH) analogues, most
of which involve goserelin. These studies will provide data from
over 4000 patients and are the first major trials of adjuvant
endocrine therapy since the initiation of the tamoxifen adjuvant
trials in 1977. The results of these trials will add considerably
to the existing database on the long-term effects of ovarian
ablation/suppression in women with early breast cancer, and are
keenly awaited.
Goserelin is an established, well-tolerated and convenient
therapy for the management of advanced breast cancer in
premenopausal and perimenopausal women (Kaufmann et al, 1989,
1991; Blamey et al, 1992, 1993, 1996). Its potential role as an adju-
vant treatment for early disease in such patients, however, remains
to be defined. A number oflarge, randomized, multicentre trials are
currently in progress to evaluate the safety andefficacy ofgoserelin
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in comparison with the current standard treatments in early breast
cancer - chemotherapy or tamoxifen. This paper provides an
outline ofthe protocols and main objectives ofthese trials.
ZOLADEX EARLY BREAST CANCER RESEARCH
ASSOCIATION (ZEBRA) TRIAL
The ZEBRA trial (Blamey et al, 1996; Jonat et al, 1998) has been
designed to address the key question of the relative merits of
endocrine manipulation or cytotoxic chemotherapy on the course
ofearly breast cancer. It is an international, open, phase III trial, in
which premenopausal and perimenopausal patients have been
randomized to receive adjuvant therapy with:
* goserelin, 3.6 mg every 28 days, for 2 years;
* six cycles ofthe standard combination ofcyclophosphamide,
methotrexate and 5-fluorouracil (CMF) (Figure 1).
This trial was first initiated in Germany by the German
Adjuvant Breast Cancer Group (GABG) and has now extended to
include other European countries, Argentina and Australia. This
trial has now completed recruitment, and includes 1640 patients
under the age of 50 years with stage II, node-positive, oestrogen
receptor (ER)-positive or unknown receptor status tumours.
The objectives ofthe trial are:
* to compare disease-free survival rates, overall survival rates
and tolerability profiles between endocrine manipulation and
chemotherapy;
* to perform a subgroup assessment ofthe effect ofgoserelin
and CMF treatment on bone mineral density;
* to perform a subgroup assessment ofquality oflife data.
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Goserelin, 3.6 mg/
28 days for2 years
Surgery ± Randomize 1:1 radiotherapy
CMF, six 28-day
cycles
Figure 1 Protocol for the ZEBRA trial of goserelin vs CMF
treatment
Recruitment for this trial commenced in October 1990 and closed
in December 1996. The timing of the efficacy analyses is depen-
dent on the number ofdisease recurrences, but it is hoped that the
first data will be available in early 1999.
CANCER RESEARCH CAMPAIGN (CRC) TRIAL
The CRC adjuvant breast cancer trial (Blamey et al, 1996; Wells
et al, 1997) is a four-arm, multinational, European trial.
Approximately 2500 patients under 50 years of age with node-
negative (stage I) or node-positive (stage II) breast cancer have
been recruited. After surgery and standard therapy (radiotherapy
and/or chemotherapy), if indicated, patients are randomized into
four treatment groups to receive:
* goserelin, 3.6 mg every 28 days, for 2 years;
* tamoxifen, 20 mg daily, for 2 years;
* goserelin plus tamoxifen for 2 years;
* no further treatment (Figure 2).
The objectives ofthe trial are to determine the effects ofovarian
suppression with goserelin, compared with adjuvant tamoxifen or
the combination ofgoserelin plus tamoxifen, on the time to disease
recurrence and overall survival rate. A subprotocol is available, if
required, to assess the risks and benefits of the different treatment
options in patients who received primary radiotherapy.
Recruitment commenced in November 1987 and is still continuing
(March 1998). Preliminary results are expected in the near future.
INTERNATIONAL BREAST CANCER STUDY
GROUP (IBCSG) VIII TRIAL
The IBCSG VIII trial (Simpson, 1991; Goldhirsch et al, 1994;
Blamey et al, 1996) is an intermational study, planning to enrol a
minimum of 1200 premenopausal and perimenopausal women
with axillary node-negative breast cancer. After surgery, patients
are randomized to receive:
* goserelin for 2 years;
* six cycles ofCMF;
* six cycles ofCMF followed by goserelin for 1.5 years (Figure 3).
This was initially a four-arm trial and included a no-treatment
group. However, the fourth treatment arm was discontinued after 2
years of recruitment as it was felt that the benefits of adjuvant
therapy were proven in this patient population and it would be
unethical to continue with a no-treatment arm.
The objectives ofthis trial are:
* to determine whether the addition ofgoserelin after six cycles
ofCMF reduces the relapse rate or prolongs survival
compared with either treatment alone;
* to carry out a quality of life analysis to investigate patient
well-being during treatment, after treatment but before relapse,
and after relapse.
Recruitment commenced in April 1990 and the trial is still in
progress (March 1998).
EASTERN COOPERATIVE ONCOLOGY GROUP
(ECOG)ISOUTH WESTERN ONCOLOGY GROUP
(SWOG) TRIAL
This collaborative trial, organized by ECOG/SWOG in the USA,
is a three-arm, multicentre, phase III comparison of combination
chemotherapy versus chemoendocrine therapy in premenopausal
patients with node-positive, ER-positive breast cancer (Cheson,
1991; Simpson, 1991; Blamey et al, 1996). After surgery, patients
were randomized to receive:
* six cycles ofcyclophosphamide, doxorubicin and 5-fluoro-
uracil (CAF);
* six cycles ofCAF followed by goserelin, 3.6 mg every
28 days, for 5 years;
* six cycles ofCAF followed by goserelin plus tamoxifen,
20 mg daily, for 5 years (Figure 4).
The objectives ofthe trial are:
* to compare recurrence rates, disease-free intervals and survival
times between the three treatment arms;
* to assess the relative toxicity ofthe three regimens;
* to assess the relative effects on hormone levels (luteinizing
hormone, oestradiol and follicle-stimulating hormone).
Goserelin, 3.6 mg/
28 days for 2 years
Tamoxifen, 20 mg
day- for 2 years
Surgery Standard Randomize 1:1:1:1
therapy Goserelin, 3.6 mg/
28 days PLUS
tamoxifen 20 mg
day-1 for 2 years
No further
treatment
Figure 2 Protocol for the CRC trial of goserelin vs tamoxifen vs the
combination vs no further treatment
Goserelin, 3.6 mg/
28 days for 2 years
Surg Randomize 1:11 _|CMF, six 28-day -Randomize 1:1:1 cycles
CMF, six 28-day
cycles followed
by goserelin,
3.6 mg/28 days
for 1.5 years
Figure 3 IBCSG VIII trial of goserelin vs CMF vs the combination. Originally
there was a fourth arm (no treatment) which was discontinued 2 years after
recruitment
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Table 1 Summary of current trials of goserelin in early breast cancer
Trial Patient subgroup(s) Treatment Comparator regimen(s)
duration
Goserelin alone
ZEBRA Node-positive 2 years CMF, six cycles
(stage 2)
IBCSG VIII Node-negative 2 years (1) CMF, six cycles
(2) CMF, six cycles followed by
goserelin for 1.5 years
CRC Node-negative 2 years (1) Tamoxifen for 2 years
(stage 1) or node-positive (2) Tamoxifen plus goserelin
(stage I1) for 2 years
(3) No further treatment
CAF followed by goserelin
ECOG/SWOG Node-positive Six cycles plus 5 (1) CAF six cycles
years (2) CAF six cycles followed by
goserelin plus tamoxifen for 5
years
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